Anixa Biosciences Inc (NASDAQ:ANIX) Short Interest Update

Anixa Biosciences Inc (NASDAQ:ANIX) was the target of a significant increase in short interest in December. As of December 31st, there was short interest totaling 1,002,532 shares, an increase of 26.0% from the December 15th total of 795,400 shares. Approximately 4.1% of the company’s stock are short sold. Based on an average trading volume of 292,147 shares, the short-interest ratio is currently 3.4 days. Based on an average trading volume of 292,147 shares, the short-interest ratio is currently 3.4 days. Approximately 4.1% of the company’s stock are short sold.

Institutional Trading of Anixa Biosciences

A number of hedge funds have recently bought and sold shares of ANIX. Vanguard Group Inc. increased its position in shares of Anixa Biosciences by 2.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,422,342 shares of the company’s stock valued at $4,694,000 after purchasing an additional 29,436 shares during the last quarter. CIBC Bancorp USA Inc. bought a new position in Anixa Biosciences during the third quarter valued at about $51,000. Susquehanna International Group LLP grew its position in Anixa Biosciences by 378.4% during the third quarter. Susquehanna International Group LLP now owns 80,387 shares of the company’s stock valued at $265,000 after buying an additional 63,584 shares during the period. Prosperity Wealth Management Inc. increased its holdings in Anixa Biosciences by 14.5% during the third quarter. Prosperity Wealth Management Inc. now owns 41,800 shares of the company’s stock worth $138,000 after buying an additional 5,300 shares during the last quarter. Finally, Citadel Advisors LLC raised its position in Anixa Biosciences by 31.6% in the third quarter. Citadel Advisors LLC now owns 96,010 shares of the company’s stock worth $317,000 after acquiring an additional 23,072 shares during the period. 29.13% of the stock is currently owned by institutional investors.

Anixa Biosciences Price Performance

NASDAQ ANIX opened at $3.19 on Monday. The company has a fifty day moving average price of $3.88 and a 200-day moving average price of $3.60. The firm has a market cap of $106.48 million, a price-to-earnings ratio of -9.11 and a beta of 0.49. Anixa Biosciences has a 1 year low of $2.33 and a 1 year high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last issued its quarterly earnings data on Monday, January 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.09). On average, research analysts anticipate that Anixa Biosciences will post -0.41 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on ANIX shares. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 target price on shares of Anixa Biosciences in a research report on Friday, December 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Anixa Biosciences in a research note on Monday, December 29th. Zacks Research downgraded shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 18th. Finally, Wall Street Zen upgraded shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a report on Saturday. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $9.00.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.